• 1
    Druker BJ,Tamura S,Buchdunger E,Ohno S,Segal GM,Fanning S,Zimmrmann J,Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 5616.
  • 2
    Kindler T,Breitenbuecher F,Kasper S,Stevens T,Carius B,Gschaidmeier H,Huber C,Fischer T. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 2003; 17: 9991009.
  • 3
    Goldberg Z,Levav Y,Krichevsky S,Fibach E,Haupt Y. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004; 3: 118895.
  • 4
    Irwin MS,Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001; 12: 3379.
  • 5
    Ramadan S,Terrinoni A,Catani MV,Sayan AE,Knight RA,Mueller M,Krammer PH,Melino G,Candi E. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 2005; 331: 71317.
  • 6
    Rodicker F,Putzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003; 63: 273741.
  • 7
    Sanchez-Prieto R,Sanchez-Arevalo VJ,Servitja JM,Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002; 21: 9749.
  • 8
    Parmar S,Katsoulidis E,Verma A,Li Y,Sassano A,Lal L,Majchrzak B,Ravandi F,Tallman MS,Fish EN,Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279: 2534552.
  • 9
    Jacquel A,Colosetti P,Grosso S,Belhacene N,Puissant A,Marchetti S,Breittmayer JP,Auberger P. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 2007; 26: 244558.
  • 10
    Liu JH,Mu ZM,Chang KS. PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med 1995; 181: 196573.
  • 11
    Ferbeyre G,de Stanchina E,Querido E,Baptiste N,Prives C,Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14: 201527.
  • 12
    Pearson M,Carbone R,Sebastiani C,Cioce M,Fagioli M,Saito S,Higashimoto Y,Appella E,Minucci S,Pandolfi PP,Pelicci PG. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 20710.
  • 13
    Bischof O,Kirsh O,Pearson M,Itahana K,Pelicci PG,Dejean A. Deconstructing PML-induced premature senescence. EMBO J 2002; 21: 335869.
  • 14
    Pearson M,Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 2001; 20: 72506.
  • 15
    Puccetti E,Beissert T,Güller S,Li JE,Hoelzer D,Ottmann OG,Ruthardt M. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 2003; 22: 69008.
  • 16
    Faderl S,Talpaz M,Estrov Z,O'Brien S,Kurzrock R,Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 16472.
  • 17
    Bernassola F,Salomoni P,Oberst A,Di Como CJ,Pagano M,Melino G,Pandolfi PP. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 154557.
  • 18
    Bernardi R,Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 2003; 22: 904857.
  • 19
    Dobbelstein M,Strano S,Roth J,Blandino G. p73-induced apoptosis: a question of compartments and cooperation. Biochem Biophys Res Commun 2005; 331: 68893.
  • 20
    Law JC,Ritke MK,Yalowich JC,Leder GH,Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 1993; 17: 104550.
  • 21
    Fleckenstein DS,Uphoff CC,Drexler HG,Quentmeier H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res 2002; 26: 20714.
  • 22
    Grob TJ,Novak U,Maisse C,Barcaroli D,Lüthi AU,Pirnia F,Hügli B,Graber HU,De Laurenzi V,Fey MF,Melino G,Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8: 121323.
  • 23
    Jensen K,Shiels C,Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001; 20: 722333.
  • 24
    Urist M,Tanaka T,Poyurovsky MV,Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004; 18: 304154.
  • 25
    Uddin S,Lekmine F,Sharma N,Majchrzak B,Mayer I,Young PR,Bokoch GM,Fish EN,Platanias LC. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000; 275: 2763440.
  • 26
    Raman M,Chen W,Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 310012.
  • 27
    Ge B,Gram H,Di Padova F,Huang B,New L,Ulevitch RJ,Luo Y,Han J. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 2002; 295: 12914.
  • 28
    Kumar S,Jiang MS,Adams JL,Lee JC. Pyridinylimidazole compound SB203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 1999; 263: 82531.
  • 29
    Galan-Moya EM,Hernandez-Losa J,Aceves Luquero CI,de la Cruz-Morcillo MA,Ramírez-Castillejo C,Callejas-Valera JL,Arriaga A,Aranburo AF,Ramón y Cajal S,Silvio Gutkind J,Sánchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin-based therapy. Int J Cancer 2008; 122: 28997.
  • 30
    Hu Y,Liu Y,Pelletier S,Buchdunger E,Warmuth M,Fabbro D,Hallek M,Van Etten RA,Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 45361.
  • 31
    Yang S,Kuo C,Bisi JE,Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002; 4: 86570.
  • 32
    Yang S,Jeong JH,Brown AL,Lee CH,Pandolfi PP,Chung JH,Kim MK. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem 2006; 281: 2664554.
  • 33
    Melino G,Bernassola F,Ranalli M,Yee K,Zong WX,Corazzari M,Knight RA,Green DR,Thompson C,Vousden KH. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004; 279: 807683.
  • 34
    Cory S,Huang DC,Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590607.